financetom
Business
financetom
/
Business
/
OptiNose Says US FDA Approves Xhance to Treat Chronic Rhinosinusitis
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
OptiNose Says US FDA Approves Xhance to Treat Chronic Rhinosinusitis
Mar 15, 2024 1:46 PM

04:25 PM EDT, 03/15/2024 (MT Newswires) -- OptiNose ( OPTN ) said Friday the US Food and Drug Administration has approved Xhance nasal spray for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 years of age and older.

Xhance combines a a widely used nasal steroid with the Exhalation Delivery System to target inflammation sites, the firm said.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Okta Insider Sold Shares Worth $45,826,688, According to a Recent SEC Filing
Okta Insider Sold Shares Worth $45,826,688, According to a Recent SEC Filing
Jan 27, 2025
05:16 PM EST, 01/27/2025 (MT Newswires) -- Jacques Frederic Kerrest, Director, on January 23, 2025, sold 524,993 shares in Okta ( OKTA ) for $45,826,688. SEC Filing: https://www.sec.gov/Archives/edgar/data/1660134/000166013425000006/xslF345X05/wk-form4_1738015930.xml ...
SoFi Stock Falls On Soft Guidance Despite 'Strong Quarter' With Record Member Growth, Loan Originations: Analyst
SoFi Stock Falls On Soft Guidance Despite 'Strong Quarter' With Record Member Growth, Loan Originations: Analyst
Jan 27, 2025
SoFi Technologies, Inc. ( SOFI ) reported better-than-expected fourth-quarter financial results. However, the company's fiscal 2025 profit guidance dragged the stock down during Monday's session. Here's a look at some details from SoFi's earnings call and early analyst reactions.  The San Francisco-based company posted earnings of 5 cents per share, beating estimates of 4 cents per share. Its revenue came...
NBT Bancorp Q4 Non-GAAP Earnings, Revenue Rise
NBT Bancorp Q4 Non-GAAP Earnings, Revenue Rise
Jan 27, 2025
05:11 PM EST, 01/27/2025 (MT Newswires) -- NBT Bancorp ( NBTB ) reported Q4 non-GAAP earnings Monday of $0.77 per diluted share, compared with $0.72 a year earlier. Analysts polled by FactSet expected $0.77 a share. Revenue for the quarter ended Dec. 31, expressed as the sum of net interest income and non-interest income, was $148.5 million, up from $137.7...
Madrigal Pharmaceuticals Insider Sold Shares Worth $531,020, According to a Recent SEC Filing
Madrigal Pharmaceuticals Insider Sold Shares Worth $531,020, According to a Recent SEC Filing
Jan 27, 2025
05:15 PM EST, 01/27/2025 (MT Newswires) -- William John Sibold, Director, President and CEO, on January 24, 2025, sold 1,584 shares in Madrigal Pharmaceuticals ( MDGL ) for $531,020. Following the Form 4 filing with the SEC, Sibold has control over a total of 54,303 shares of the company, with 54,303 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1157601/000162828025002666/xslF345X05/wk-form4_1738015934.xml ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved